Answers are grounded in this paper and cite their sources.
Background The impact of type 2 diabetes mellitus (T2DM) and glucose levels on clinical outcomes in patients with gastric cancer after neoadjuvant immunotherapy remains unclear. We assessed mean baseline glucose and T2DM status in relation to pathologic response and survival. Methods This retrospective cohort study included patients with gastric cancer who received NICT followed by surgery at three medical centers in China from 2021 to 2024. Random venous glucose levels within 4 weeks before ICI initiation, and T2D status, OS and PFI were collected. Results Among 376 patients, 86 (22.9%) had diabetes and 91 (24.2%) achieved pCR. Compared with the lowest glucose quartile, the highest quartile had a lower pCR rate (14.9% vs 28.0%) and lower adjusted odds of pCR (OR 0.33, 95% CI 0.15 to 0.74, P = 0.007). The adjusted HR for OS comparing the highest with the lowest quartile was 3.42 (95% CI 0.97 to 12.01, P = 0.055). PFI did not differ significantly across quartiles (log-rank P = 0.189). Diabetes was not associated with pCR or survival. Among 175 patients with available CPS data, CPS ≥ 5 was associated with higher odds of pCR and longer OS and PFI after adjustment. HbA1c was not significantly associated with treatment outcomes in the 59 patients with available data. Conclusion Higher mean baseline glucose was associated with poorer pathologic response and shorter survival for gastric cancer patients underwent NIT. These findings highlight the value of baseline glucose assessment and glycemic control may improve treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: